Team
Michael Reilly - CEO and Co-Founder
- 35 years of international leadership experience in marketing, business development, finance, and strategy at Amgen, Baxter, Sanofi, and Sterling Drug
- Co-leader of 20 development teams in neuroscience and other therapeutic areas including the blockbuster denosumab valued over $11B
- Member of core team on acquisition of Immunex and Enbrel®, the largest in biotech history at $16B
- BA, Molecular Biology, University of California, Berkeley & MBA, University of Michigan, Ann Arbor
Douglas Sears, MD - CMO and Co-Founder
- Former Director of the ADHD Clinic at the Cedars Sinai Medical Center in Los Angeles, California.
- Licensed and board certified physician specializing in child, adolescent and adult psychiatry.
- Over two decades of experience in his field serving as a clinician, consultant, program director and educator.
- MD, University of Southern California
H. Christian Fibiger, PhD - Scientific Advisor
- Assistant Dean, Research, and Professor Emeritus in the Faculty of Medicine at the University of British Columbia.
- Former Vice President and Global Head of Neuroscience at Amgen, the world's largest biotechnology company. Responsible for Amgen’s worldwide neuroscience discovery efforts, ranging from early exploratory research through clinical candidate selection
- Before joining Amgen in 2003, Dr. Fibiger served as Vice President of Neuroscience Discovery Research and Clinical Investigation, and Lilly Research Laboratories Europe at Eli Lilly and Company.
- Among the top 100 most cited scientists in neuroscience. He has received numerous honors for his research contributions, including the Clark Institute Prize in Psychiatry and the Heinz Lehmann Award of the Canadian College of Neuropsychopharmacology
- Past coeditor of Neuropsychopharmacology: the official publication of the American College of Neuropsychopharmacology.
- BSc in Chemistry and Psychology from the University of Victoria and his PhD in Psychopharmacology from Princeton University.
